title: Clinical efficacy comparison of HA280 and DNA280 immunoadsorption column in treating systemic lupus erythematosus.
abstract: OBJECTIVE
  The aim of this study was to compare the efficacy of HA280 and DNA280 immunoadsorption (IA) column in treating systemic lupus erythematosus (SLE), and provide the basis for seeking cost-effective solution for SLE.
  
  
  METHODS
  Fifty-seven severe SLE patients receiving IA treatment from January 2007 to December 2013 were selected. They were divided into HA280 group (31 cases) and DNA280 group (26 cases), which used HA280 and DNA280 IA column, respectively. The efficacy, adverse reactions, and hospitalization cost of the two groups were compared.
  
  
  RESULTS
  Both two groups could effectively reduce the SLE-associated antibodies, immunoglobulins, complement levels, serum creatinine, blood urea nitrogen, and 24-h urine protein levels (P < 0.05). The efficiency and incidence of adverse reactions of two groups were similar (P > 0.05), while the hospitalization cost of HA280 group was significantly less than that of DNA280 group (P < 0.05).
  
  
  CONCLUSIONS
  Application of HA280 IA column in IA treatment is relatively the most cost-effective adjuvant therapy to severe SLE.
authors.affiliation: a Department of Nephrology , The Third Hospital of Zhengzhou , Zhengzhou , China.
authors.forename: Lan
authors.initials: L
authors.lastname: Xu
authors.affiliation: a Department of Nephrology , The Third Hospital of Zhengzhou , Zhengzhou , China.
authors.forename: Xianming
authors.initials: X
authors.lastname: Wu
authors.affiliation: a Department of Nephrology , The Third Hospital of Zhengzhou , Zhengzhou , China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zou
mesh_terms: D000293:Adolescent; D000328:Adult; D002315:Cardiopulmonary Bypass; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone
keywords: DNA280; Efficacy; HA280; Immunoadsorption; Systemic lupus erythematosus